Wegovy and Ozempic, side-by-side A few caveats about the drugs follow, but keep in mind with the marketplace driving much of the thinking, and clinical experience evolving, there may be changes in store: Wegovy is FDA-approved for chronic weight loss management in adults 18 years of age or older with a BMI of 30 or BMI 27 and at least one medical condition related to obesity (e.g., diabetes, hypertension, etc.)
Alcohol will likely affect you more quickly
Wegovy (semaglutide) and Mounjaro (tirzepatide) are peptides, and peptides can be broken down in the digestive tract before they are absorbed
Classically, three metabolic alterations have been identified that contribute to the development of T2DM: 1) insulin resistance, 2) an eventual decrease in insulin secretion from pancreatic beta cells, and 3) an excess production of glucose from the liver